uniQure (QURE)
Develops one-time AAV gene therapies for serious diseases with unmet needs.
Something off on this page? Send us feedback.
Develops one-time genomic medicines through an AAV platform and proprietary manufacturing. Its business pairs partnered HEMGENIX rights and supply with proprietary programs led by investigational Huntington’s therapy AMT-130.
Develops one-time genomic medicines for serious diseases through an AAV platform and proprietary manufacturing. The core business combines internal drug development with external commercialization, including a licensing and supply relationship with CSL Behring around HEMGENIX.
Advances proprietary programs led by AMT-130 for Huntington’s disease. That therapy remains investigational; the FDA communication identified its analysis as a potential basis for an accelerated-approval BLA, while further alignment on the confirmatory-study design was still required before the intended submission.
Operates from an Amsterdam origin with a U.S. public listing and a manufacturing facility in Lexington, Massachusetts. Glybera’s EU authorization expired after uniQure did not seek renewal because of lack of demand, distinguishing regulatory authorization from durable commercial demand.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 30, 2026 | Barclays | Reiterate | Rating: —Target: $65 | Target: $60 |
| Jul 30, 2026 | Wolfe Research | Upgrade | ||
| Jul 29, 2026 | Wolfe Research | Upgrade | ||
| Jun 29, 2026 | H.C. Wainwright | Target | Target: $50 | Target: $80 |
| Jun 25, 2026 | Mizuho Securities | Target | Target: $33 | Target: $68 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $810.3M · Total debt $62.8M · Total assets $985.1M · Shareholders' equity $324.1M
- Revenue
- $5.8M
- Operating income
- −$55.9M
- Net income
- −$81.1M
No dividends on record.
| Institutions | 94.86% | 65.80M shares | |
|---|---|---|---|
| 302 holders · as of Jun 30, 2026 | |||
| Insiders | 2.00% | 1.39M shares | |
| 12 holders · as of Jul 7, 2026 | |||
| Strategic holders | 10.40% | 7.22M shares | |
| 2 holders · as of Feb 13, 2026 | |||
| Adds to | 107.26% | ||
69.37M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 107.26%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Avoro Capital Advisors LLCInstitution | 9.70% | 6.73M | as of Jun 30, 2026 |
JPMorgan Chase & CoInstitution | 7.02% | 4.87M | as of Jun 30, 2026 |
RTW Investments, LPInstitution | 5.68% | 3.94M | as of Jun 30, 2026 |
Aberdeen Group plcStrategic | 5.30% | 3.68M | filed Jan 29, 2026 |
G1 Execution Services, LLCStrategic | 5.10% | 3.54M | filed Feb 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 2, 2026 | Matthew C. Kapusta | director, officer: CEO, Managing Director | −21,082 | $45.16 |
| Jun 30, 2026 | Jack Kaye | director | −21,167 | $46.44 |
| Jun 30, 2026 | Walid Abi-Saab | officer: Chief Medical Officer | −30,000 | $46.42 |
| Jun 26, 2026 | Walid Abi-Saab | officer: Chief Medical Officer | −1,434 | $46.86 |
| Jun 25, 2026 | Matthew C. Kapusta | director, officer: CEO, Managing Director | −28,716 | $50.02 |
- PTC Therapeutics
Oral huntingtin-lowering program in global Phase 3
- Wave Life Sciences
Allele-selective mutant huntingtin-lowering program
- Alnylam Pharmaceuticals
Phase 1 RNAi program targeting HTT exon 1
- Neurocrine Biosciences
Approved once-daily treatment for Huntington's chorea
- Teva (ADR)
Approved VMAT2 inhibitor for Huntington's chorea
- Sarepta Therapeutics
First-in-human CNS-delivered siRNA HD program
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| uniQure | $45.45 | +0.40% | $3.07B | — | — | 164.6 | +11.0% |
| PTC Therapeutics | $65.96 | +0.02% | $5.45B | — | 53.3 | 5.4 | +101.6% |
| Wave Life Sciences | $4.35 | 0.00% | $838.4M | — | — | 12.8 | −73.9% |
| Alnylam Pharmaceuticals | $339.41 | +34.98% | $32.69B | 41.3 | 29.9 | 6.8 | +66.9% |
| Neurocrine Biosciences | $142.25 | +0.01% | $14.48B | 21.1 | 15.6 | 4.3 | +39.5% |
| Teva (ADR) | $39.60 | +0.28% | $46.66B | 66.8 | 14.1 | 2.7 | −0.8% |
| Sarepta Therapeutics | $20.86 | +0.19% | $2.13B | — | 36.2 | 1.1 | −34.3% |
| Median | 41.3 | 29.9 | 4.8 | +19.3% |